Verastem Oncology (NASDAQ: VSTM) will present new clinical data from its'avutometinib and defactinib program at the International Gynecologic Cancer Society Annual Global Meeting in Montreal, running October 1-3, 2026.
All presentations are scheduled for Friday, October 2. A late-breaking oral session from 10:30 a.m. to 11:30 a.m. ET will cover molecular profiling and tumor biomarker analysis from the phase 2 RAMP 201 trial. Another seminal oral presentation during the same window will report results from the RAMP 201J study, which enrolled Japanese patients. A poster presentation at 2:25 p.m. ET will feature an external control arm analysis comparing the drug combination against standard-of-care therapy.
The programs targetKRAS-mutated recurrent low-grade serous ovarian cancer in adult patients who have received prior systemic therapy. Low-grade serous ovarian cancer is a rare subtype characterized by high recurrence rates and lower sensitivity to chemotherapy compared with high-grade serous disease. An estimated 6,000 to 8,000 women in the United States and 80,000 worldwide are affected annually.
RAMP 201 is an adaptive, multicenter, parallel-cohort, randomized, open-label phase 2 trial evaluating the efficacy and safety of avutometinib alone and in combination with defactinib.
The FDA granted accelerated approval for'avutometinib plus defactinib (marketed as AVMAPKI FAKZYNJA CO-PACK) on May 8, 2025, based on tumor response rate and duration of response. Continued approval remains contingent on confirmation of clinical benefit in a confirmatory trial.
